Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off

GSK reports Blenrep outperforms in phase III multiple myeloma trial

Published Nov 27, 2023 08:12
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
GSK
+0.36%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GSK
+0.96%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

GSK has disclosed encouraging results from its phase III DREAMM-7 trial, revealing that Blenrep (belantamab mafodotin) has shown effectiveness as a second-line treatment for relapsed or refractory multiple myeloma. The trial, which compared Blenrep plus BorDex to daratumumab plus BorDex, involved 494 patients who had previously undergone therapy but experienced disease progression. The independent review recommended early unblinding due to promising interim outcomes, with Blenrep demonstrating a significant improvement in progression-free survival (PFS) and a positive overall survival (OS) trend.

The study's primary endpoint of PFS was met, and further analyses are ongoing to assess other key measures such as OS, duration of response, and rates of minimal residual disease negativity. GSK's team, led by Hesham Abdullah, is preparing to present detailed findings from the interim analysis soon.

Blenrep's mechanism involves targeting the B-cell maturation antigen to deliver auristatin F, a cytotoxic agent, using technologies licensed from Seagen Inc. and BioWa Inc. This innovative approach aims to address the challenges of treating multiple myeloma, which is often considered manageable but not curable.

With the safety profiles consistent with previous data, GSK anticipates communicating these findings with health authorities for potential further action. For detailed safety information regarding Blenrep's use in the European Union, stakeholders are referred to consult the European Medicines Agency (EMA) reference guide provided by GSK.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

GSK reports Blenrep outperforms in phase III multiple myeloma trial
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email